Pancreatic cancer, EMA approves a tablet against the disease: how it works

The European Medicines Agency has approved the new medicine against metastatic pancreatic cancer. Already approved in the United States, daraxonrasib, a tablet drug, offers important improvements in terms of survival, which is why the EMA's Committee for Medicinal Products for Human Use has recommended granting marketing authorization in the European Union.

The Committee's positive opinion represents an important step, but does not yet equate to definitive authorization in the EU. The decision now rests with the European Commission, which will have to decide on the basis of the EMA's scientific evaluation. Here's everything you need to know.